A New Era of Patient-Led Innovation
Patient groups oftentimes serve as the authority on a specific disease when it comes to advancing research. “Without patient perspective, there is no good medical product development,” Rachel Sherman,…
Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993.
Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration(FDA) and has been prescribed to several thousand patients in the United States.[3]
As of 2014 the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[4][5] It gained EU approval in February 2017.[6] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[7][8]
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck’s pembrolizumab (Keytruda) and Bristol Myers Squibb’s nivolumab (Opdivo).[9][10]
Novartis acquired Incyte’s c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma.[11]
Patient groups oftentimes serve as the authority on a specific disease when it comes to advancing research. “Without patient perspective, there is no good medical product development,” Rachel Sherman,…
Pfizer has teamed up with Bain Capital to launch Cerevel Therapeutics, a biopharmaceutical company based in Boston that will focus on developing treatments for a number of central nervous system…
After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from…
Richie Etwaru is founder and CEO of Hu-manity, whose vision is to empower people to take ownership of their inherent human data. The pharmaceutical industry has never seen the full…
The opioid epidemic has reached new heights of late, claiming an estimated 40,000 American lives every year. The highly addictive nature of opium-derived medicine is the cause of the rising…
Meghann Chilcott, Senior Vice President of OrderInsite, discusses the changing role of pharmacists and technicians. Patients are consumers, and they expect more from pharmacies than a collection of pill…
Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMSS) for PharmaBoardroom. We must assertively bend the arc of technology towards our patients,…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it? The UK’s National Health Service has crippling…
Pfizer today announced that Dr. Albert Bourla its Chief Operating Officer (COO) will succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role…
Today the USA finds itself in the midst of an opioid crisis, claiming 40,000 American lives every year – a comparable death toll to the HIV epidemic at its peak.…
It has been a robust first half in 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities. Deal-tracking sources demonstrate M&A values witnessed meaningful increases…
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
See our Cookie Privacy Policy Here
